Eric Jonasch, Md, On Which Non-Metastatic Renal Cell Cancer Patients Should Receive Adjuvant Therapy

Eric Jonasch, MD, on which non-metastatic renal cell cancer patients should receive adjuvant therapy

Eric Jonasch, MD, on treating non-metastatic renal cell carcinoma patients with adjuvant therapy

Eric Jonasch, MD, on approaches to consider with metastatic non-clear renal cell carcinoma

Mohamad E. Allaf, MD, on non-metastatic renal cell cancer patients and adjuvant therapy

Eric Jonasch, MD, on targeted therapies used to treat non-clear cell renal cell carcinoma

Dr. Jonasch on Single-Agent Pembrolizumab in Non-Clear Cell RCC

Brain Metastases and Kidney Cancer: Insights from Dr. Eric Jonasch (MD Anderson Cancer Center)

Dr. Jonasch on Alternative Sunitinib Scheduling for mRCC

Eric Jonasch, MD, on integrating immunotherapies into renal cell carcinoma treatment algorithms

Dr. Jonasch on Sequencing Challenges in RCC

Dr. Jonasch on the CABOSUN Trial in RCC

What can patients do to mitigate side effects from kidney cancer treatment?

Kidney Cancer Association

ESMO22 Highlights: Dr. Jonasch Discusses the COSMIC313 Trial for Kidney Cancer

Unmet Needs in the Adjuvant Setting for Renal Cell Carcinoma

Dr. Jonasch on the Potential of Immunotherapy for Sarcomatoid RCC

#KCRS19: Eric Jonasch, M.D.

Eric Jonasch, MD, expounds on the use of MK-6482 in both RCC and non-RCC tumors

Dr. Jonasch on First- and Second-line Options for Patients With RCC

Systemic targeted therapy for metastatic renal cell carcinoma in 2012 Eric Jonasch, M.D

Systemic treatment options for patients with metastatic non-clear cell renal cell carcinoma